🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT06779058
Recruiting

MR Elastography for Assessing Liver Fibrosis in Chronic Hepatitis B

NCT06779058 · tracked via the Priya Life Science China tracker
Sponsor
Shengjing Hospital
Phase
Started
2025-01-01
Last updated
2026-02-27

Condition(s) studied

Chronic Hepatitis BLiver Fibrosis

Investigational drug(s) / intervention(s)

MRELiver biopsy

MRE: All imaging studies were performed by using a 1.5T/3.0-T MRI system

Liver biopsy: Liver biopsy are performed by well-trained pathologists in accordance with standard operating procedures.

Study summary

How to construct a non-invasive, accurate, and convenient method to evaluate the severity of liver fibrosis (LF) is an important general problem in the management of patients with chronic hepatitis B (CHB). We plan to investigate the ability of magnetic resonance elastography (MRE) to grade fibrosis in chronic hepatitis B and apply to clinical longitudinal follow-up.

Eligibility

Sex
ALL
Min age
18 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria: * Age ≥ 18 years old * Confirmed CHB (laboratory, imaging and clinical tests) * MRE within 6 months before and after liver biopsy * Treatment-naïve * Child-Pugh Grade A (\<7 points) * Written informed consent in prospective follow-up cohort Exclusion Criteria: * Patients with liver malignant tumor * Chronic hepatitis due to other causes (such as alcoholic hepatitis) * CHB combined with hepatitis C, hepatitis D, or HIV * Patients with biliary tract diseases * Contraindications of MRE examination, MRE failure * Poor pathological effect

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Shengjing Hospital Shenyang Liaoning Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06779058 on ClinicalTrials.gov ↗ ← All trials in China